Siddhartha Kadia - 01 Sep 2023 Form 4 Insider Report for NUVASIVE INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Sep 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Sep 2023, 16:53:49 UTC
Prior SEC filing: 28 Aug 2023
Next SEC filing: 03 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/ Nathaniel B. Sisitsky, Attorney-in-Fact for Siddhartha Kadia

Key filing fact

Siddhartha Kadia filed Form 4 for NUVASIVE INC on 05 Sep 2023.

Key facts

This page summarizes Siddhartha Kadia's Form 4 filing for NUVASIVE INC.
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Sep 2023, 16:53.

Change

Previous filing in this sequence was filed on 28 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NUVA transaction

Common Stock, par value $0.001 per share

Disposed to Issuer

Transaction value
Shares: -3,739
Change %: -100%
Price
Shares after: 0
Date: 01 Sep 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVA transaction Derivative

Restricted Stock Unit

Disposed to Issuer

Transaction value: $0
Shares: -3,788
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,788
Exercise price
Footnotes: F2, F3

NUVA transaction Derivative

Restricted Stock Unit

Disposed to Issuer

Transaction value: $0
Shares: -4,816
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,816
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Siddhartha Kadia is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.

Footnote F2

Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

Footnote F3

Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.